Association of baseline sleep quality with trajectories of depressive symptoms in patients undergoing interferon treatment

Psychosomatic Medicine

Volumn 77, Issue 8, 2015, Pages 911-920

  Marron, Megan M ^a   Anderson, Stewart J ^a   Garrity, Jessica ^b   Reynolds, Charles F ^b   Lotrich, Francis E ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

depression; group based trajectory modeling; hepatitis C virus; sleep quality

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; SLEEP DISORDER; SLEEP QUALITY; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT DURATION; CHEMICALLY INDUCED; CLASSIFICATION; COMPLICATION; MIDDLE AGED; SLEEP WAKE DISORDERS;

ADULT; ANTIVIRAL AGENTS; DEPRESSION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; SLEEP WAKE DISORDERS;

EID: 84944054319     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0000000000000231     Document Type: Article

References (101)

1. Insel TR, Charney DS. Research on major depression strategies and priorities. JAMA 2003;289:3167-8.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3.
3. Panzarino PJJ. The costs of depression: direct and indirect; treatment versus nontreatment. J Clin Psychiatry 1998;59 (suppl 20):1-141.
4. Coyne JC, Fechner-Bates S, Schwenk TL. Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry 1994;16:267-76.
5. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013;346:f2539.
6. Kim J. Depression as a psychosocial consequence of occupational injury in the US working population: findings from the medical expenditure panel survey. BMC Public Health 2013;13:303.
7. Lucas M, Mirzaei F, O'Reilly EJ, Pan A, Willett WC, Kawachi I, Koenen K, Ascherio A. Dietary intake of n-3 and n-6 fatty acids and the risk of clinical depression in women: A 10-y prospective follow-up study. Am J Clin Nutr 2011;93:1337-43.
8. Sanchez-Villegas A, Henríquez P, Figueiras A, Ortuño F, Lahortiga F, Martínez-González MA. Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study. Eur J Nutr 2007;46:337-46.
9. Herique A, Kahn JP. Guidelines and reality in practical use of and compliance to antidepressants in the treatment of depression: incidence survey in Lorraine and Champagne-Ardenne. Encéphale 2009;35:73-9.
10. Patten SB, Lee RC. Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov model. Med Decis Making 2004;24:351-8.
11. Kruijt A-W, Antypa N, Booij L, de Jong PJ, Glashouwer K, Penninx BWJH, Van der Does W. Cognitive reactivity, implicit associations, and the incidence of depression: A two-year prospective study. PLoS One 2013;8:e70245.
12. Patten SB. Long-Term medical conditions and major depression in a Canadian population study at Waves 1 and 2. J Affect Disord 2001;63:35-41.
13. Blazer DG. Mood disorders: epidemiology. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2000; 1298-307.
14. Eaton WW, Kramer M, Anthony JC, Dryman A, Shapiro S, Locke BZ. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1989;79:163-78.
15. Boyes AW, Girgis A, D'Este CA, Zucca AC, Lecathelinais C, Carey ML. Prevalence and predictors of the short-Term trajectory of anxiety and depression in the first year after a cancer diagnosis: A population-based longitudinal study. J Clin Oncol 2013;31:2724-9.
16. Green KM, Fothergill KE, Robertson JA, Zebrak KA, Banda DR, EnsmingerME. Early life predictors of adult depression in a community cohort of urban African Americans. J Urban Health 2013;90:101-15.
17. Gonzalez HM, Tarraf W, Whitfield KE, Vega WA. The epidemiology of major depression and ethnicity in the United States. J Psychiatr Res 2010;44:1043-451.
18. Patten SB. Recall bias and major depression lifetime prevalence. Soc Psychiatry Psychiatr Epidemiol 2003;38:290-6.
19. GimenoD, KivimakiM, Brunner EJ, Elovainio M, DeVogli R, Steptoe A, Kumari M, Lowe GDO, Rumley A, Marmot MG, Ferrie JE. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009;39:413-23.
20. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011;13:467-75.
21. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-41.
22. Slopen N, Kubzansky LD, McLaughlin KA, Koenen KC. Childhood adversity and inflammatory processes in youth: A prospective study. Psychoneuroendocrinology 2013;38: 188-200.
23. van Zuiden M, Heijnen CJ, van de Schoot R, Amarouchi K, MaasM, Vermetten E, Geuze E, Kavelaars A. Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: A prospective, longitudinal study. PLoS One 2011;6:e29142.
24. Kaufman HL, Kirkwood JM, Hodi F, Agarwala S, Amatruda T, Bines SD, Clark J, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, SharfmanW, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013;10:588-98.
25. Mocellin S, LensMB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013;6:CD008955.
26. Tarhini AA, Gogas H, Kirkwood JM. IFN-Alpha in the treatment of melanoma. J Immunol 2012;189:3789-93.
27. Kent S, Bluthé R-M, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24-8.
28. Charlton BG. The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses 2000;54:126-30.
29. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-62.
30. Lotrich FE. Inflammatory cytokines, growth factors, and depression. Curr Pharm Des 2012;18:5920-35.
31. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-Alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009;65:344-8.
32. Lotrich FE, Rabinovitz F, Gironda P, Pollock BG. Depression following pegylated interferon-Alpha: characteristics and vulnerability. J Psychosom Res 2007;63:131-5.
33. Udina M, Castellvi P, Moreno-Espana J, Navinés R, Valdés M, Forns X, Langohr K, Solà R, Vieta E, Martín-Santos R. Interferon-induced depression in chronic hepatitis C: A systematic review and meta-Analysis. J Clin Psychiatry 2012; 73:1128-38.
34. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-Alpha treatment. Psychiatry Res 2010;177:240-5.
35. Reichenberg A, Gorman JM, Dieterich DT. Interferoninduced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. AIDS 2005;19 (suppl 3):S174-8.
36. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-A-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-12.
37. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.Mol Psychiatry 2002;7:942-7.
38. Castera L, Constant A, Henry C, Champbeniot P, Bernard PH, de Ledinghen V, Demotes-Mainard J, Couzigou P. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006;24:1223-30.
39. Schaefer M, Schmidt F, Horn M, Schmid-Wendtner MH, Volkenandt M. Depression during treatment with interferon alpha. Psychosomatics 2004;45:176.
40. Janssen H, Brouwer J, van der Mast R, Schalm S. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3.
41. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11.
42. Castera L, Constant A, Henry C, Couzigou P. Psychiatric disorders during treatment of chronic hepatitis C. Gastroenterol Clin Biol 2005;29:123-33.
43. Dan AA, Martin LM, Crone C, Ong JP, FarmerDW, Wise T, Robbins SC, Younossi ZM. Depression, anemia and healthrelated quality of life in chronic hepatitis C. J Hepatol 2006; 44:491-8.
44. Younossi Z, Kallman J, Kincaid J. The effects of HCVinfection and management on health-related quality of life. Hepatology 2007;45:806-16.
45. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am 2014;98:17-38.
46. Janssen Research & Development. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients. October 24. Press Release. 2013.
47. Gilead Sciences. FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection. October 25. Press Release. 2013.
48. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 2014;109:628-35.
49. Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Haussinger D, ShiffmanML, Hadziyannis SJ, SchmidtWN, Jacobson IM, Barcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. Long-Term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin. J Viral Hepat 2013;20:524-9.
50. Hsu HC. Group-based trajectories of depressive symptoms and the predictors in the older population. Int J Geriatr Psychiatry 2012;27:854-62.
51. Andreescu C, Chang CC, Mulsant BH, Ganguli M. Twelveyear depressive symptom trajectories and their predictors in a community sample of older adults. Int Psychogeriatr 2008;20:221-36.
52. Liang J, Xu X, Quinones AR, Bennett JM, Ye W. Multiple trajectories of depressive symptoms in middle and late life: racial/ethnic variations. Psychol Aging 2011;26:761-77.
53. Kuchibhatla MN, Fillenbaum GG, Hybels CF, Blazer DG. Trajectory classes of depressive symptoms in a community sample of older adults. Acta Psychiatr Scand 2012;125: 492-501.
54. Prather A, Rabinvitz M, Pollock B, Lotrich F. Cytokineinduced depression during IFN-A treatment: The role of IL-6 and sleep quality. Brain Behav Immun 2009;23:1109-16.
55. FirstMB, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV (SCID-1) (Users Guide and Interview) Research Version. New York: Biometrics Research Department, New York Psychiatric Institute; 1995.
56. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-48.
57. Beck A, Steer R, Garbin M. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100.
58. Beck A, Steer R, Brown G.Manual for the Beck Depression Inventory-II. SanAntonio, TX: Psychological Corporation; 1996.
59. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193-213.
60. Hall M, Buysse DJ, Nowell PD, Nofzinger EA, Houck P, Reynolds CF 3rd, Kupfer DJ. Symptoms of stress and depression as correlates of sleep in primary insomnia. Psychosom Med 2000;62:227-30.
61. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002;53:737-40.
62. Roeder K, Lynch KG, Nagin DS. Modeling uncertainty in latent class membership: A case study in criminology. J Am Stat Assoc 1999;447:766-76.
63. Jones B, Nagin D, Roeder K. A SAS procedure based on mixture model for estimating developmental trajectories. Sociol Methods Res 2001;29:374-93.
64. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
65. Nagin D. Group-Based Modeling of Development. Cambridge, MA: Harvard University Press; 2005.
66. Niyonkuru C, Wagner AK, Ozawa H, Amin K, Goyal A, Fabio A. Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: A practical example. J Neurotrauma 2013;30:938-45.
67. Lincoln KD, Takeuchi DT. Variation in the trajectories of depressive symptoms: results fromthe Americans' Changing Lives Study. Biodemogr Soc Biol 2010;56:24-41.
68. Li X, Wang W, Gao Q, Wu L, Luo Y, Tang Z, Guo X. The trajectories and correlation between physical limitation and depression in elderly residents of Beijing, 1992-2009. PLoS One 2012;7:e42999.
69. Salguero JM, Cano-Vindel A, Iruarrizaga I, Fernandez-Berrocal P, Galea S. Trajectory and predictors of depression in a 12-month prospective study after the Madrid March 11 terrorist attacks. J Psychiatr Res 2011;45:1395-403.
70. Christensen AL, Stuart EA, Perry DF, Le HN. Unintended pregnancy and perinatal depression trajectories in lowincome, high-risk Hispanic immigrants. Prev Sci 2011;12: 289-99.
71. Ferro MA, Speechley KN. Stability of latent classes in group-based trajectory modeling of depressive symptoms in mothers of children with epilepsy: An internal validation study using a bootstrapping procedure. Soc Psychiatry Psychiatr Epidemiol 2013;48:1077-86.
72. Updegraff KA, Perez-Brena NJ, Umana-Taylor AJ, Jahromi LB, Harvey-Mendoza EC. Mothers' trajectories of depressive symptoms across Mexican-origin adolescent daughters' transition to parenthood. J Fam Psychol 2013;27:376-86.
73. Sabiston CM, O'Loughlin E, Brunet J, ChaitonM, Low NC, Barnett T, O'Loughlin J. Linking depression symptomtrajectories in adolescence to physical activity and teamsports participation in young adults. Prev Med 2013;56:95-8.
74. Reinke WM, Eddy JM, Dishion TJ, Reid JB. Joint trajectories of symptoms of disruptive behavior problems and depressive symptoms during early adolescence and adjustment problems during emerging adulthood. J Abnorm Child Psychol 2012; 40:1123-36.
75. Doyle F, McGee H, Delaney M, Motterlini N, Conroy R. Depressive vulnerabilities predict depression status and trajectories of depression over 1 year in persons with acute coronary syndrome. Gen Hosp Psychiatry 2011; 33:224-31.
76. Kaptein KI, de Jonge P, van den Brink RH, Korf J. Course of depressive symptoms after myocardial infarction and cardiac prognosis: A latent class analysis. Psychosom Med 2006;68:662-8.
77. Johansson P, Lesman-Leegte I, Lundgren J, Hillege HL, Hoes A, Sanderman R, van Veldhuisen DJ, Jaarsma T. Time-course of depressive symptoms in patients with heart failure. J Psychosom Res 2013;74:238-43.
78. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behav Immun 2002;16:575-80.
79. Donnelly S. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 1998;25:921-7.
80. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998;37: 93-7.
81. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-26.
82. Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30:213-8.
83. Hayashino Y, Yamazaki S, Takegami M, Nakayama T, Sokejima S, Fukuhara S. Association between number of comorbid conditions, depression, and sleep quality using the Pittsburgh Sleep Quality Index: results from a populationbased survey. Sleep Med 2010;11:366-71.
84. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84.
85. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39: 411-8.
86. Riemann D, Voderholzer U. Primary insomnia: A risk factor to develop depression? J Affect Disord 2003;76:255-9.
87. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 1997; 146:105-14.
88. Gregory AM, O'Connor TG. Sleep problems in childhood: A longitudinal study of developmental change and association with behavioral problems. J Am Acad Child Adolesc Psychiatry 2002;41:964-71.
89. Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rossler W. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008;31:473-80.
90. Roberts RE, Roberts CR, Chen IG. Impact of insomnia on future functioning of adolescents. J Psychosom Res 2002; 53:561-9.
91. Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep 2008; 31:1351-6.
92. Gregory AM, Rijsdijk FV, Lau JY, Dahl RE, Eley TC. The direction of longitudinal associations between sleep problems and depression symptoms: A study of twins aged 8 and 10 years. Sleep 2009;32:189-99.
93. Hagnell O, Lanke J, Rorsman B, Ojesjo L. Are we entering an age of melancholy? Depressive illnesses in a prospective study epidemiological study over 25 years: The Lundby Study. Psychol Med 1982;12:279-89.
94. Rhebergen D, Lamers F, Spijker J, de Graaf R, Beekman AT, Penninx BW. Course trajectories of unipolar depressive disorders identified by latent class growth analysis. Psychol Med 2012;42:1383-96.
95. Clapp JD, Grubaugh AL, Allen JG, Mahoney J, Oldham JM, Fowler JC, Ellis T, Elhai JD, Frueh BC. Modeling trajectory of depressive symptoms among psychiatric inpatients: A latent growth curve approach. J Clin Psychiatry 2013;74:492-9.
96. Vreeburg SA, Hoogendijk WJG, DeRijk RH, van Dyck R, Smit JH, Zitman FG, Penninx BW. Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. Psychoneuroendocrinology 2013;38:1494-502.
97. van Mill JG, Vogelzangs N, van Someren EJW, Hoogendijk WJG, Penninx BWJH. Sleep duration, but not insomnia, predicts the 2-year course of depressive and anxiety disorders. J Clin Psychiatry 2014;75:119-26.
98. Cronkite RC, Woodhead EL, Finlay A, Timko C, Unger Hu K, Moos RH. Life stressors and resources and the 23-year course of depression. J Affect Disord 2013;150:370-7.
99. Melchior M, Chastang JF, Head J, Goldberg M, Zins M, Nabi H, Younes N. Socioeconomic position predicts longterm depression trajectory: A 13-year follow-up of theGAZEL cohort study. Mol Psychiatry 2013;18:112-21.
100. Hovens JGFM, Giltay EJ, Wiersma JE, Spinhoven P, Penninx BWJH, Zitman FG. Impact of childhood life events and trauma on the course of depressive and anxiety disorders. Acta Psychiatr Scand 2012;126:198-207.
101. Witek Janusek L, Tell D, Albuquerque K, Mathews HL. Childhood adversity increases vulnerability for behavioral symptoms and immune dysregulation in women with breast cancer. Brain Behav Immun 2013;30(suppl):S149-62.